Transgene SA

ENXTPA:TNG 株式レポート

時価総額：€210.9m

Transgene 将来の成長

Future 基準チェック /26

Transgeneは、3.3%と76.1%でそれぞれ年率3.3%で利益と収益が成長すると予測される一方、EPSはgrowで24.2%年率。

主要情報

3.3%

収益成長率

24.18%

EPS成長率

Biotechs 収益成長58.1%
収益成長率76.1%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日30 Apr 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • Jun 05

TNG: Phase II Head And Neck Data Will Drive Future Repricing

Analysts have adjusted their fair value estimate for Transgene stock to €1.10 per share. This change reflects updated assumptions on discount rates, profit margins and a significantly higher future P/E multiple in their models.
ナラティブの更新 • Apr 23

TNG: Phase II Head And Neck Progress Will Drive Future Repricing

Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.
ナラティブの更新 • Apr 09

TNG: Phase I Head And Neck Data Will Support Future Repricing

Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.
ナラティブの更新 • Mar 25

TNG: Phase I Head And Neck Data Will Drive Future Repricing

Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).
ナラティブの更新 • Mar 11

TNG: Phase I Head And Neck Vaccine Data Will Support Future Repricing

Analysts have maintained their price target for Transgene at €1.10, reflecting largely stable assumptions on the discount rate, revenue trends, margins, and future P/E expectations. What's in the News Transgene released a preprint on medRxiv with a comprehensive analysis of clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine.
ナラティブの更新 • Feb 24

TNG: Phase I Head And Neck Data Will Drive Future Repricing

Analysts have reduced their price target for Transgene to €1.10 from €2.00, reflecting updated assumptions that include a higher discount rate, lower revenue growth expectations, improved profit margin and a lower future P/E multiple. What's in the News Transgene released a preprint on medRxiv detailing clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine for operable head and neck cancers (medRxiv preprint).
ナラティブの更新 • Feb 10

TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential

Analysts have adjusted their price target on Transgene slightly, reflecting updated assumptions for a discount rate, revenue growth of 33.57% and a forward P/E of 27.97x, while keeping fair value at €1.10. This suggests a more finely tuned view of the company’s risk and earnings profile rather than a major shift in outlook.
ナラティブの更新 • Jan 26

TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential

Analysts have adjusted their price target for Transgene, citing updated assumptions on discount rate, revenue growth, profit margin and a lower future P/E multiple as key drivers of the change in valuation. The new target is presented in line with a fair value estimate of €1.10 per share.
ナラティブの更新 • Jan 12

TNG: Clinical Progress And Capital Raise Will Support Future Upside

Analysts have adjusted their price target for Transgene, citing updated assumptions that keep fair value at €1.10 while reflecting different views on revenue growth, profit margins, and a higher future P/E multiple. What's in the News Preprint publication on medRxiv shares clinical and translational data from the Phase I part of Transgene's randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine, with the manuscript also submitted to a peer reviewed journal for evaluation (Product related announcement).
ナラティブの更新 • Dec 14

TNG: Pipeline Progress And Stronger Balance Sheet Will Drive Future Upside

Analysts have moderately reduced their price target on Transgene, cutting fair value by about 20 percent to approximately 1.10 euros. They have incorporated slower expected revenue growth, a higher discount rate, and a more balanced, though significantly improved, long term profit margin outlook into their models.
分析記事 • May 27

Is Transgene (EPA:TNG) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
User avatar
新しいナラティブ • Apr 07

TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines

Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.
分析記事 • Jun 15

Is Transgene (EPA:TNG) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Mar 21

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

One thing we could say about the analysts on Transgene SA ( EPA:TNG ) - they aren't optimistic, having just made a...
分析記事 • Mar 19

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Last week, you might have seen that Transgene SA ( EPA:TNG ) released its full-year result to the market. The early...
分析記事 • Mar 18

Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Nov 24

Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Apr 16

Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Mar 12

What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?

Every investor in Transgene SA ( EPA:TNG ) should be aware of the most powerful shareholder groups. Insiders often own...

業績と収益の成長予測

ENXTPA:TNG - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202857-25-25-181
12/31/20277-62-60-591
12/31/20267-38-40-391
12/31/20257-38-38-37N/A
9/30/20257-37-31-30N/A
6/30/20258-37-24-23N/A
3/31/20257-35-25-23N/A
12/31/20246-34-27-24N/A
9/30/20246-28-33-30N/A
6/30/20246-23-39-36N/A
3/31/20247-23-38-35N/A
12/31/20238-22-37-35N/A
9/30/20238-28-36-34N/A
6/30/20239-33-35-33N/A
3/31/202310-33-28-26N/A
12/31/202210-33-22-20N/A
9/30/202214-28-18-17N/A
6/30/202218-23-15-15N/A
3/31/202218-21-21-20N/A
12/31/202117-20-27-26N/A
9/30/202113-23-29-28N/A
6/30/20219-27-31-30N/A
3/31/20219-22-30-29N/A
12/31/202010-17-30-29N/A
9/30/202012-11-31-30N/A
6/30/202014-6-33-31N/A
3/31/202014-12-28-27N/A
12/31/201913-19-24-22N/A
9/30/201911-6N/A-23N/A
6/30/201988N/A-23N/A
3/31/201988N/A-25N/A
12/31/201878N/A-28N/A
9/30/20187-10N/A-29N/A
6/30/20187-29N/A-30N/A
3/31/20187-31N/A-33N/A
12/31/20177-32N/A-35N/A
9/30/20178-32N/A-36N/A
6/30/20179-31N/A-37N/A
3/31/20179-28N/A-35N/A
12/31/201610-24N/A-34N/A
9/30/201610-26N/A-37N/A
6/30/20169-28N/A-40N/A
3/31/20169-33N/A-43N/A
12/31/201510-38N/A-45N/A
9/30/201510-40N/A-48N/A
6/30/201510-42N/A-50N/A

アナリストによる今後の成長予測

収入対貯蓄率: TNG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TNG今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: TNG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TNGの収益 ( 76.1% ) French市場 ( 5.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: TNGの収益 ( 76.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TNGの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/11 00:47
終値2026/06/11 00:00
収益2025/12/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Transgene SA 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5

アナリスト機関
Arsene GuekamCIC Market Solutions (ESN)
Michael Thomas CooperEdison Investment Research
Martial DescouturesODDO BHF Corporate & Markets